Theresa L O'Keefe from 20 Richgrain Ave, Waltham, MA 02453, age 63, Phone: 6176454767

Managing Partner

view source

Location:

Waltham, MA

Industry:

Biotechnology

Work:

Pharma-Cycle Inc - Newport, RI since Oct 2011
Chief Scientific Officer
The Research Network - Sandwich, Kent, UK since Oct 2011
Network Partner – Antibodies and Biotherapeutics
Boston University Kindle Mentor Program - Boston, MA since Jul 2011
Mentor, Biotherapeutics
Pfizer Pharmaceuticals Jul 2010 - Jun 2011
Director, Protein Biology, Global Biotherapeutics
Waltham Technologies Inc Feb 2007 - Jun 2010
Co-founder and Chief Scientific Officer

Education:

Tufts University Sackler School of Biomedical Sciences 1986 - 1992
Ph.D., Immunology Purdue University 1984 - 1986
M.S., Veterinary Physiology Mount Holyoke College 1980 - 1984
A.B. cum laude, Biochemistry and Biological Sciences

Skills:

Drug Discovery
Immunology
Biotechnology
Molecular Biology
Protein Chemistry
Cell
Life Sciences
Biopharmaceuticals
Clinical Development
Oncology
Drug Development
Pharmaceutical Industry
Lifesciences
Clinical Trials
Cell Biology
Cancer
Inflammation
Fda
Infectious Diseases
Pharmacology
Biochemistry
Purification
Technology Transfer
Assay Development
Cro
Cell Culture
Vaccines
Antibodies
Science
Biomarker Discovery
In Vitro
Elisa
Neuroscience
In Vivo
Biomarkers
Glp
Genomics
Flow Cytometry

Senior Scientist

view source

Location:

20 Richgrain Ave, Waltham, MA 02453

Industry:

Biotechnology

Work:

Chiesi Usa, Inc.
Senior Scientist

Associate Professor Of The Practice , School Of Theology And Ministry

view source

Location:

11 Vinal St, Brighton, MA 02135

Industry:

Higher Education

Work:

Boston College since Sep 2005
Assistant Professor, School of Theology and Ministry
Boston College - Boston since Sep 2005
Director of Contextual Education, School of Theology and Ministry
Roman Catholic Diocese of Springfield MA 1990 - 2000
Consultant on Religious Education

Education:

Boston College 2000 - 2006
PhD, Theology & Education Boston College 1988 - 1990
MEd, Religious Education University of Toronto - University of St. Michael's College 1981 - 1985
BA, Religious Studies

Skills:

Teaching
Theology
Curriculum Development
Leadership
Student Development
Higher Education
Religion
Public Speaking
Social Justice
Nonprofits
Youth Ministry
Youth Development
Religious Studies
Program Development
Academic Writing
Student Affairs
Adult Education
Practical Theology
Supervising
Supervisory Training
Student Advising
Pastoral Theology
Young Adult Ministry

Theresa O'keefe

view source

Theresa O'keefe

view source

Us Patents

Monoclonal Antibodies Against Hmgb1
view source
US Patent:

7288250, Oct 30, 2007
Filed:

Sep 10, 2004
Appl. No.:

10/938992
Inventors:

Walter Newman - Boston MA, US
Shixin Qin - Lexington MA, US
Theresa L. O'Keefe - Waltham MA, US
Robert A. Obar - Walpole MA, US
Assignee:

Critical Therapeutics, Inc. - Lexington MA
International Classification:

A61K 39/395
C07K 16/24
US Classification:

4241331, 4241451, 435810, 435335, 435355, 5303873, 5303881, 53038823
Abstract:

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7442775, Oct 28, 2008
Filed:

Jan 27, 2004
Appl. No.:

10/766610
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 23/00
A61K 39/00
C12N 15/00
US Classification:

5303879, 536 2353, 4353201, 435328
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Rage Protein Derivatives
view source
US Patent:

7470521, Dec 30, 2008
Filed:

Jul 20, 2005
Appl. No.:

11/186422
Inventors:

Theresa O'Keefe - Waltham MA, US
Peter Luciano - Maynard MA, US
Shixin Qin - Lexington MA, US
Assignee:

Critical Therapeutics, Inc. - Lexington MA
International Classification:

C12P 21/06
A61K 39/00
C07H 21/04
C12P 21/04
C12N 5/00
C12N 5/16
C12N 15/64
C12N 1/20
US Classification:

435 691, 4241921, 536 234, 435 697, 435325, 4353441, 435 914, 4352523
Abstract:

The present invention is drawn to fusion proteins comprising a Receptor for Advanced Glycation Endproducts (RAGE) and an immunoglobulin element. The invention also encompasses methods of treating a condition characterized by activation of an inflammatory cytokine cascade comprising administering such fusion proteins. The invention is also drawn to nucleic acids encoding the fusion proteins, as well as vectors and cells comprising such nucleic acids.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7473421, Jan 6, 2009
Filed:

Jan 27, 2004
Appl. No.:

10/766773
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Radlett, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07K 16/00
A61K 39/02
US Classification:

4241391, 435 696, 435 5
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

7566450, Jul 28, 2009
Filed:

Oct 26, 2007
Appl. No.:

11/924794
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher J. Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - London, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 39/395
US Classification:

4241391, 4241421, 4241431
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Monoclonal Antibodies Against Hmgb1
view source
US Patent:

7632500, Dec 15, 2009
Filed:

Sep 20, 2007
Appl. No.:

11/903129
Inventors:

Walter Newman - Boston MA, US
Shixin Qin - Lexington MA, US
Theresa L. O'Keefe - Waltham MA, US
Robert A. Obar - Walpole MA, US
Assignee:

Cornerstone Therapeutics, Inc. - Cary NC
International Classification:

A61K 39/395
C07K 16/24
US Classification:

4241341, 4241451, 435810, 5303873
Abstract:

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

High Affinity Antibodies Against Hmgb1 And Methods Of Use Thereof
view source
US Patent:

8129130, Mar 6, 2012
Filed:

Mar 18, 2011
Appl. No.:

13/051327
Inventors:

Herren Wu - Boyds MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US
Jane Tian - North Potomac MD, US
Theresa O'Keefe - Waltham MA, US
Shixin Qin - Lexington MA, US
Assignee:

The Feinstein Institute for Medical Research - Manhasset NY
MedImmune, LLC - Gaithersburg MD
International Classification:

G01N 33/53
US Classification:

435 72
Abstract:

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

Humanized Anti-Ccr2 Antibodies And Methods Of Use Therefor
view source
US Patent:

8227211, Jul 24, 2012
Filed:

Sep 23, 2008
Appl. No.:

12/235765
Inventors:

Gregory J. LaRosa - Newton MA, US
Christopher Horvath - Taunton MA, US
Walter Newman - Boston MA, US
S. Tarran Jones - Hertfordshire, GB
Siobhan H. O'Brien - Herts, GB
Theresa O'Keefe - Waltham MA, US
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 39/395
C12N 15/13
C07K 16/00
US Classification:

435 696, 43525231, 43525233, 43525411, 435375, 4241331, 5303873
Abstract:

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e. g. , human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.